Dr Kaklamani talks to ecancertv at SABCS 2015 about results from the ongoing, prospective Trial Assigning Individualized Options for Treatment (TAILORx) involving more than 10,000 women with estrogen receptor (ER)-positive, HER2-negative, axillary…
from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1ZqIORV
via IFTTT
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1RIqpPp
via IFTTT
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1VbXgL7
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου